Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Organ Site Research

Abstract C41: No difference in mortality between racial groups after prostate cancer diagnosis given equal access to health care

Afsheen Hasan, Mohamed Kamel, Rodney Davis and Joseph Su
Afsheen Hasan
University of Arkansas for Medical Sciences, Little Rock, AR.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Kamel
University of Arkansas for Medical Sciences, Little Rock, AR.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney Davis
University of Arkansas for Medical Sciences, Little Rock, AR.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Su
University of Arkansas for Medical Sciences, Little Rock, AR.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7755.DISP16-C41 Published February 2017
  • Article
  • Info & Metrics
Loading
Abstracts: Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2016; Fort Lauderdale, FL

Abstract

Introduction: Prostate cancer (PCa) is the leading incident cancer and the second leading cause of cancer death among American men. African Americans (AAs) suffer a disproportionate burden of disease with 1.5 times higher incidence and more than double the mortality rates of European American (EA) men. AAs tend to be diagnosed with more virulent forms of the disease and at earlier ages than other racial/ethnic groups, which cannot be explained completely by differences in socioeconomic status or access to care. However, it is unclear whether there is significant difference in mortality between racial groups after PCa diagnosis (Dx) given equal access to health care. This study will evaluate if the mortality of AA is higher than other racial groups after PCa Dx using data from five Veterans Affairs (VA) medical facilities in the mid-south region.

Methods: A retrospective review of medical records from five VA hospitals in the mid-south was conducted. All prostate cancer patients diagnosed between January 2009 and December 2014 at these hospitals were included. Primary endpoint was overall survival. Vital status of patients was updated through December 2015. PCa patients were categorized into 3 categories of aggressiveness, i.e., high, intermediate, and low, based on clinical presentation at Dx, including Prostate-specific antigen (PSA) levels, Gleason Sum, and cancer stage. Multivariate Cox proportional hazard models were used to examine the risk of mortality after PCa Dx adjusting for age, marital status, tobacco history, alcohol history, PCa aggressiveness, and first course of treatment option with race as the primary predictive factor.

Results: After excluding 23 patients who did not report race, 11 pacific islanders, and 27 American Indian, Aleutian, Eskimo/Asian Indian, the dataset included 4,740 PCa patients of which, 2,327 patients were EAs and 2,413 were AAs. During this five year period, 545 deaths were reported, where 50.5% were EAs and 49.5% were AAs. As expected, high PCa aggressiveness vs. low/intermediate aggressiveness (Hazard Ratio (HR) = 1.33, 95% Confidence Interval (CI) = 1.08-1.63), distant metastasis at Dx (HR = 5.05, 95%CI = 3.81-6.71), and age (HR = 1.07, 95%CI = 1.06-1.07) were statistically significantly associated with mortality after PCa Dx. Using radiation therapy as reference, surgery as the first course of treatment (HR = 0.61, 95%CI = 0.45-0.82) was inversely associated with mortality after PCa Dx, while hormonal therapy and active surveillance were not significantly associated with mortality after PCa Dx. However, a non-statistically significant association was observed between AAs and mortality (HR=1.14, 95% CI=0.96-1.35, p = 0.14) when compared to EAs.

Conclusion: There was no significant difference between AAs and EAs in mortality after PCa Dx in this medical review of PCa patients in five VA hospitals in the mid-south. Although genetic, environmental, and lifestyle factors may contribute to the difference in PCa mortality observed between racial groups, AA race is not a significant contributor to death when given equal access to health care, such as in the VA hospital setting.

Citation Format: Afsheen Hasan, Mohamed Kamel, Rodney Davis, Joseph Su. No difference in mortality between racial groups after prostate cancer diagnosis given equal access to health care. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr C41.

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Epidemiology Biomarkers & Prevention: 26 (2 Supplement)
February 2017
Volume 26, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract C41: No difference in mortality between racial groups after prostate cancer diagnosis given equal access to health care
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract C41: No difference in mortality between racial groups after prostate cancer diagnosis given equal access to health care
Afsheen Hasan, Mohamed Kamel, Rodney Davis and Joseph Su
Cancer Epidemiol Biomarkers Prev February 1 2017 (26) (2 Supplement) C41; DOI: 10.1158/1538-7755.DISP16-C41

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract C41: No difference in mortality between racial groups after prostate cancer diagnosis given equal access to health care
Afsheen Hasan, Mohamed Kamel, Rodney Davis and Joseph Su
Cancer Epidemiol Biomarkers Prev February 1 2017 (26) (2 Supplement) C41; DOI: 10.1158/1538-7755.DISP16-C41
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Organ Site Research

  • Abstract A74: [Advocate Abstract:] The brown faces of colorectal cancer
  • Abstract A82: Disparities in prostate cancer incidence, patient and clinical characteristics among Latino subpopulations defined by country of origin in California: Findings from the California Cancer Registry
  • Abstract A69: Racial disparity in breast cancer hospital treatment costs: Examining the effect of depression
Show more Organ Site Research

Genitourinary Cancers

  • Abstract A82: Disparities in prostate cancer incidence, patient and clinical characteristics among Latino subpopulations defined by country of origin in California: Findings from the California Cancer Registry
  • Abstract A79: Establishment of African American prostate cancer patient-derived primary cell lines and xenografts
  • Abstract A83: Decreased nuclear expression of the E3 ubiquitin ligase Nrdp1 in African American men compared to Caucasian men with localized prostate cancer
Show more Genitourinary Cancers

Genitourinary Cancers: Poster Presentations - Proffered Abstracts

  • Abstract A82: Disparities in prostate cancer incidence, patient and clinical characteristics among Latino subpopulations defined by country of origin in California: Findings from the California Cancer Registry
  • Abstract A79: Establishment of African American prostate cancer patient-derived primary cell lines and xenografts
  • Abstract A83: Decreased nuclear expression of the E3 ubiquitin ligase Nrdp1 in African American men compared to Caucasian men with localized prostate cancer
Show more Genitourinary Cancers: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement